Impressions | 21st Edition

Campbell Arnold
2 days ago
3 min read

“They're trying to move the decision-making point as far forward as possible because they don't have enough doctors.”

— David Specht, CEO MAUI Imaging

Welcome to RadAccess: Impressions—your quick-read companion to the main RadAccess newsletter. Here we only deliver the essential information. For more details, you can always turn to the full RadAccess newsletter.

In this issue, we cover:

HOPPR Releases First Commercial Product—Aims to Make AI Development Easier
MAUI Imaging Secures $14M to Push Ultrasound’s Boundaries
1,247 FDA-Authorized AI Medical Devices, and Counting!
RSNA Launches Multimodal Aneurysm Detection Challenge

If you want to stay up-to-date with the latest in Radiology and AI, then don't forget to subscribe!

Subscribe Here

HOPPR Releases First Commercial Product—Aims to Make AI Development Easier

HOPPR has launched its first commercial product, the Marie Curie Chest Radiography Foundation Model, marking an early move into “foundation-models-as-a-service” for radiology. The model is designed to be fine-tuned and integrated into downstream devices and workflows. Even in its initial release, the model performed on par with Microsoft’s MedImageInsight and Google’s MedGemma across 28 benchmarks and has already enabled partners like DeepHealth to rapidly fine-tune and deploy models, cutting down development costs and timelines. HOPPR’s platform aims to lower development barriers by providing validated infrastructure, experiment tracking, and regulatory support. The company also plans to add additional modalities, functionality, and in-house data services, positioning itself as a key infrastructure provider for AI development in medical imaging.

MAUI Imaging Secures $14M to Push Ultrasound’s Boundaries

MAUI Imaging has raised a $14M Series D funding round to advance its novel ultrasound system, Multiple Aperture Ultrasound Insonification (MAUI), which can see through barriers like bone and gas that limit traditional devices. The technology has the potential to replace CT or MRI in certain trauma situations. The portable device is already FDA-cleared for standard ultrasound and now aims to expand claims for “see-through” imaging using the Series D funding. With total funding reaching $40M, MAUI could bridge the gap between ultrasound and high-cost imaging systems, enabling deeper insights at the point of care.

1,247 FDA-Authorized AI Medical Devices, and Counting!

The FDA reported clearing 1,247 AI-enabled medical devices in their latest report, with radiology leading the way at 76.7%. The top five companies—GE, Siemens, Philips, Canon, and United Imaging—are all major OEMs, with GE out front for the fourth year in a row with 100 cleared devices. Aidoc leads among the AI-first imaging companies with 30 authorizations, while Subtle Medical and Hyperfine also earned spots in the Top 20. Looking ahead, the FDA also indicated it plans to flag devices built with foundation models, adding transparency to how these tools are developed.

RSNA Launches Multimodal Aneurysm Detection Challenge

The RSNA 2025 Intracranial Aneurysm Detection AI Challenge is the first competition to target multimodal detection across CT angiography, MR angiography, and MRI—reflecting real-world clinical practice. With over 6,500 imaging studies and 3,500 annotated aneurysms curated from 18 sites worldwide, the challenge invites researchers to build highly generalizable algorithms that can identify aneurysms across different locations. The competition is hosted on Kaggle through October 14th, with $50,000 in total prizes!

Feedback

We’re eager to hear your thoughts as we continue to refine and improve RadAccess. Is there an article you expected to see but didn’t? Have suggestions for making the newsletter even better? Let us know! Reach out via email, LinkedIn, or X—we’d love to hear from you.

References

Disclaimer: There are no paid sponsors of this content. The opinions expressed are solely those of the newsletter authors, and do not necessarily reflect those of referenced works or companies.